Mexico - Delayed Quote • MXN NeuBase Therapeutics, Inc. (NBSE.MX) Follow 21.00 0.00 (0.00%) At close: May 10 at 9:59 AM CDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for NBSE.MX 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: NBSE.MX View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations NeuBase Therapeutics Announces Receipt of Notice from Nasdaq Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance NeuBase Therapeutics Issues Statement Regarding Filing By Shareholder SYMETRYX CORPORATION ACQUIRES 20% STOCK IN NEUBASE NeuBase Therapeutics to Explore Strategic Alternatives NeuBase Announces Closing of $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules NeuBase Presents Non-Human Primate Data Illustrating Stealth Editors™ are Non-Immunogenic, Opening the Door to Redosing NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules NeuBase Announces 1-for-20 Reverse Stock Split NeuBase to Participate in Jefferies Healthcare Conference NeuBase Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors™ NeuBase Announces Formation of Gene Editing Advisory Board
